Illumina

YTD

ALL

Trade Illumina 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About ILMN

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. The company was founded by David R.

CEO

Jacob Thaysen

CEOJacob Thaysen

Employees

8,600

Employees8,600

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1998

Founded1998

Employees

8,600

Employees8,600

ILMN Key Statistics

Market cap

40.66B

Market cap40.66B

Price-Earnings ratio

50.21

Price-Earnings ratio50.21

Dividend yield

—

Dividend yield—

Average volume

2.04M

Average volume2.04M

High today

$271.64

High today$271.64

Low today

$264.42

Low today$264.42

Open price

$265.60

Open price$265.60

Volume

1.26M

Volume1.26M

52 Week high

$309.35

52 Week high$309.35

52 Week low

$94.00

52 Week low$94.00

Stock Snapshot

Illumina(ILMN) stock is priced at $269.59, giving the company a market capitalization of 40.66B. It carries a P/E multiple of 50.21.

On 2026-10-25, Illumina(ILMN) stock moved within a range of $264.42 to $271.64. With shares now at $269.59, the stock is trading +2.0% above its intraday low and -0.8% below the session's peak.

Trading activity shows a volume of 1.26M, compared to an average daily volume of 2.04M.

Over the past 52 weeks, Illumina(ILMN) stock has traded between a high of $309.35 and a low of $94.00.

ILMN News

Benzinga 2d

Here’s How Much You Would Have Made Owning Illumina Stock In The Last 20 Years - Benzinga

...

TipRanks 2d

Illumina downgraded to Equal Weight from Overweight at Stephens

Stephens downgraded Illumina (ILMN) to Equal Weight from Overweight with a price target of $275, up from $213. Published first on TheFly – the ultimate source...

Simply Wall St 3d

Should AI Genomics Tools Require Action From Illumina Investors?

Illumina introduced three early access tools on its BioInsight Platform, including DRAGEN Ultra, Workflow Orchestrator, and Learning Cohorts, aimed at helping r...

Analyst ratings

46%

of 24 ratings

Buy

45.8%

Hold

37.5%

Sell

16.7%

More ILMN News

Simply Wall St 5d

Illumina Could Be 13% Above Fair Value After BioInsight Launch

Advertisement Why Illumina’s BioInsight launch matters for the stock Illumina (ILMN) just rolled out its BioInsight Platform, a unified software environment t...

People also own

Based on the portfolios of people who own ILMN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.